Traditional cancer therapies have struggled to tackle proteins such as MYC and KRAS, which are notorious for driving aggressive tumor growth and evading most small molecule drugs and antibody-based treatments. These proteins are termed “undruggable” due to their intrinsically disordered structures and lack of well-defined binding pockets, leaving conventional drug design at a disadvantage. The Northwestern team circumvented these hurdles by developing a novel class of heterobifunctional polymers dubbed HYDRACs (HYbrid DegRAding Copolymers), which function with remarkable precision to snare and shuttle these elusive proteins toward their degradation.

The essence of HYDRAC technology lies in its dual-binding architecture. Each polymer is designed with two functional domains: one arm incorporates multiple copies of peptides capable of selectively binding target proteins like MYC and KRAS, while the other arm carries molecular cues that recruit the cell’s protein decay machinery. This bifunctional design enables the polymers to physically juxtapose the target protein with the degradation systems naturally embedded within the cell, overcoming the need for a traditional druggable pocket.

Experimental work demonstrated the efficacy of these polymers in cellular models representing a spectrum of cancers. When introduced into cultured cancer cells, HYDRACs selectively engaged MYC and KRAS proteins, resulting in their prompt degradation. This degradation halted oncogenic signaling cascades driven by these proteins, leading to cell death. More impressively, in animal models harboring tumors driven by MYC, these polymers localized preferentially within tumors and curtailed tumor progression without significant toxicity or side effects, highlighting the potential for in vivo therapeutic application.

One of the most daunting challenges in contemporary oncology is managing the mutational plasticity of cancer cells, particularly with proteins like KRAS. Although recent small molecule inhibitors have been developed for specific KRAS mutations, resistance emerges quickly as tumors evolve alternative pathways or mutate their drug-binding sites. HYDRAC-based degradation effectively neutralizes this problem by targeting the entire protein for disposal rather than inhibiting a specific site. As detailed by Professor Nathan Gianneschi—the lead researcher and a renowned expert in polymer chemistry—this method effectively drags the protein “kicking and screaming” into the cell’s degradation pathway, indifferent to mutation status or protein conformational changes.

The methodology holds promise not only for oncology but could potentially revolutionize therapeutic strategies across multiple disease domains. Neurodegenerative disorders, inflammatory conditions, and metabolic diseases often involve aberrant or harmful proteins that are challenging to target with conventional drugs. The modular design of HYDRAC polymers allows for customization against a diverse array of protein targets, effectively opening doors to a broad spectrum of proteinopathies previously deemed intractable.

From a molecular engineering perspective, the one-step polymer synthesis employed by Gianneschi’s group is particularly noteworthy. It enables rapid, scalable production of these proteomimetic polymers with high specificity and multivalency, providing multiple binding sites on a single polymer chain to increase avidity and efficacy. This synthetic flexibility stands in contrast to small molecule strategies, which often require extensive medicinal chemistry optimization and face limitations imposed by the necessity of precise binding pockets.

Moreover, the theoretical underpinning of HYDRAC’s mechanism capitalizes on cellular quality control systems such as ubiquitin-proteasome pathways and autophagy. By co-opting these endogenous pathways, HYDRACs leverage the cell’s intrinsic mechanisms for protein homeostasis rather than relying on external enzymatic activity or immune-mediated clearance. This endogenous engagement minimizes off-target effects and enhances the likelihood of sustained therapeutic response.

The successful proof-of-concept studies published by the Northwestern team demonstrate the potential for translation from bench to bedside. Northwestern’s tech transfer and associated spinout company, Grove Biopharma, are actively developing the HYDRAC platform within the framework of “Bionic Biologics,” aiming to expedite clinical application. This translational push is supported by grants from various prestigious institutes, reinforcing the significance and potential impact of this research.

Importantly, the potential for multivalent polymer-based degraders extends beyond static protein targets. Given the dynamic and disordered nature of many pathological proteins, the ability of HYDRACs to adapt to variations and mutations makes it a versatile platform that could surmount longstanding obstacles in drug resistance and target selectivity. The polymers’ capability to bind disordered regions affords a new paradigm in drug design, shifting focus from rigid lock-and-key interactions toward adaptable, multivalent binding polymers.

While much remains to be explored, including long-term safety profiles, pharmacokinetics, and efficacy across diverse human tumors, the initial data provide compelling evidence that targeted protein degradation mediated by synthetic polymers represents a viable and transformative avenue in oncology and beyond. This research not only deepens our understanding of protein biology but also pioneers a new front in the war against cancer by transforming the cell’s disposal systems into strategic allies.

The study titled “Heterobifunctional proteomimetic polymers for targeted degradation of MYC and KRAS” propels the field forward, combining meticulous polymer chemistry with cellular biology to address formidable challenges posed by disordered cancer proteins. As targeted therapies evolve, this technology points toward a future where “undruggable” proteins can be effectively eliminated rather than inhibited, offering renewed hope for patients burdened by aggressive cancers and, potentially, other devastating diseases.

Subject of Research: Animals

Article Title: Heterobifunctional proteomimetic polymers for targeted degradation of MYC and KRAS

News Publication Date: 24-Feb-2026

Web References: https://doi.org/10.1038/s41467-026-68913-3

Keywords: Cancer, Proteins, Cellular proteins, Cancer cells, Cancer treatments

MYC functions as a pivotal transcription factor that governs key aspects of cell proliferation, metabolism, and survival. Its dysregulation is implicated in roughly 70% of human cancers, underscoring its broad impact across diverse tumor types. The protein’s ability to influence cell cycle progression, apoptosis resistance, angiogenesis promotion, and immune evasion renders it a formidable driver of tumor aggressiveness. Furthermore, MYC’s involvement in mediating resistance to a variety of chemotherapeutic agents elevates its status from a mere oncogene to a significant barrier to effective treatment outcomes.

Despite its central oncogenicity, MYC has historically been labeled “undruggable.” Its intrinsically disordered structure lacks the defined pockets typically targeted by traditional small molecule drugs, and MYC’s extensive interactions across protein networks complicate direct inhibition. However, the tide is turning. Recent advancements propose interfering with the critical MYC-MAX heterodimerization, a process essential for MYC’s transcriptional activity. Disrupting this dimer formation effectively silences MYC-driven gene expression, providing a tangible therapeutic avenue.

Significant progress has been made through compounds such as OMO-103, a molecule engineered to selectively disrupt the MYC-MAX interface. Early-phase clinical evaluations reveal that OMO-103 can impede tumor proliferation by dismantling oncogenic transcription programs, signaling a breakthrough in MYC-targeted therapy. This direct blockade signifies a paradigm shift, demonstrating that with precision drug design, even proteins once considered refractory to intervention can be harnessed therapeutically.

In tandem with direct inhibition, the landscape of MYC targeting expands towards indirect strategies. One promising route involves the suppression of MYC at the transcriptional or translational level. By attenuating MYC mRNA synthesis or destabilizing its transcripts, it is possible to reduce the protein’s cellular abundance. These approaches often utilize antisense oligonucleotides, RNA interference technologies, or small molecules that interfere with transcriptional regulators upstream of MYC. Such tactics delicately balance efficacy with reduced off-target toxicity.

Moreover, promoting the degradation of existing MYC protein pools emerges as another compelling strategy. Novel proteolysis-targeting chimeras (PROTACs) exploit the cell’s inherent ubiquitin-proteasome system to tag MYC for destruction. This method executes the selective clearance of MYC without inhibiting its function directly, diversifying the arsenal against tumors addicted to this oncoprotein. PROTAC technology heralds an era where targeted protein elimination can surmount obstacles imposed by structural disarray in challenging targets like MYC.

Another layer of innovation rests in synthetic lethality approaches, designed to exploit cellular dependencies unique to MYC-overexpressing cancer cells. By identifying pathways indispensable to the survival of tumors driven by elevated MYC, researchers can deploy drugs that selectively disable these auxiliary systems, sparing normal cells that lack such reliance. This precision approach carries immense potential for minimizing collateral damage, a long-standing problem in conventional chemotherapy.

The integration of advanced small molecule inhibitors with protein degradation technologies sets the stage for combination therapies. Such regimens seek to enhance therapeutic efficacy through synergistic mechanisms, potentially overcoming monotherapy resistance that commonly hampers clinical success. Precision medicine principles guide these combinations, tailoring treatment to the tumor’s MYC expression profile and molecular context, thereby maximizing patient benefit while mitigating adverse effects.

However, the intricate biology of MYC necessitates careful consideration of context-dependent effects. MYC’s influence extends beyond tumor cells, participating in normal tissue regeneration and maintenance. Broad-spectrum or indiscriminate MYC inhibition risks impairing physiological processes, potentially leading to premature aging phenotypes or compromised tissue homeostasis. Consequently, therapeutic windows must be meticulously defined, and biomarkers of MYC activity must inform patient selection.

Advancements in molecular understanding have illuminated MYC’s extensive network of interacting partners, including transcriptional cofactors, chromatin remodelers, and signaling intermediaries. These insights allow for novel opportunities to modulate MYC’s oncogenic output indirectly by targeting critical nodes within its regulatory circuitry. Combination targeting of MYC and its ancillary pathways may reduce compensatory mechanisms that lead to therapeutic resistance, heralding more durable clinical responses.

The critical examination of MYC’s role in immune evasion also opens avenues for integrating MYC-targeted therapy with immuno-oncology. MYC’s suppression of immune surveillance mechanisms fosters an immunosuppressive tumor microenvironment. Disrupting MYC signaling could restore immune recognition and augment responses to checkpoint inhibitors or cellular immunotherapies. Such interdisciplinary treatments embody the modern holistic approach necessary to confront complex cancer biology.

In summary, the evolving narrative of MYC as an oncogenic driver and therapeutic target reveals a transition from “undruggable” enigma to an actionable gateway. The convergence of structural biology, chemical innovation, molecular genetics, and clinical research has expedited the emergence of multifaceted therapeutic modalities that directly or indirectly attenuate MYC function. This multidisciplinary momentum not only redefines the therapeutic landscape for MYC-driven cancers but also exemplifies the power of precision medicine to conquer historically intractable biological challenges.

As investigators continue to unravel the nuances of MYC regulation and exploit its vulnerabilities, the future promises novel and effective cancer treatment strategies. The story of MYC underscores the broader scientific journey from understanding fundamental oncogenic processes to translating that knowledge into transformative patient outcomes. With ongoing clinical trials and burgeoning drug development pipelines, MYC-directed therapies stand at the vanguard of oncology innovation, poised to reshape cancer care paradigms worldwide.

Subject of Research: MYC protein regulation and therapeutic targeting in oncology

Article Title: Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology

Web References:
DOI – http://dx.doi.org/10.1016/j.gendis.2024.101435

References:
Yingying Duan, Zhaoshuo Liu, Qilin Wang, Junyou Zhang, Jiaxin Liu, Ziyi Zhang, Chunyan Li, Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology, Genes & Diseases, Volume 12, Issue 4, 2025, 101435

Image Credits: Genes & Diseases

Keywords: MYC, oncogene, cancer therapy, protein degradation, PROTAC, MYC-MAX complex, synthetic lethality, small molecule inhibitors, transcription factor, drug resistance, precision medicine, immuno-oncology

Over the past decade, third-generation EGFR tyrosine kinase inhibitors (TKIs) like osimertinib have revolutionized the treatment landscape for NSCLC, particularly for patients exhibiting EGFR mutations. Despite dramatic improvements in clinical outcomes, the inevitable emergence of drug resistance remains a formidable challenge, often mediated by secondary genetic alterations such as MET amplification. This amplification leads to compensatory bypass signaling, rendering EGFR-targeted therapies less effective and limiting long-term patient survival.

The innovative research team adopted an in silico drug repurposing tool known as DRAR-CPI (Drug Repositioning Approach based on the Chemical-Protein Interactome), which leverages chemical-protein interactome analysis to systematically probe existing drugs for their potential to interfere with oncogenic proteins. By analyzing a comprehensive profile of known MET inhibitors, the team computationally screened for candidate molecules that could suppress MET activity, ultimately pinpointing fexofenadine as a unexpected but highly promising MET inhibitor candidate.

Fexofenadine, widely prescribed globally for allergic rhinitis and chronic urticaria, has an established clinical safety profile and well-characterized pharmacodynamics, making it an attractive candidate for repositioning in oncology. To validate the computational predictions, the researchers conducted a series of biochemical and cellular assays. Fexofenadine was confirmed to inhibit recombinant MET kinase activity in cell-free systems, demonstrating direct target engagement. Furthermore, in osimertinib-resistant NSCLC cell lines with MET amplification, fexofenadine significantly reduced phosphorylation of MET and downstream signaling molecules, indicating disruption of oncogenic signaling pathways responsible for therapeutic resistance.

The study extended its molecular characterization through kinome-wide profiling (KINOME scan), revealing that fexofenadine’s kinase inhibition spectrum closely resembled that of cabozantinib, an FDA-approved MET inhibitor with known anticancer efficacy. This similarity underscores the potential of fexofenadine to mimic MET-targeted pharmacological effects, albeit with an established safety and dosing paradigm derived from its long-term use in allergy treatment.

Crucially, the combinatorial treatment of fexofenadine with osimertinib in MET-amplified and EGFR T790M-mutated NSCLC cellular models produced a pronounced synergistic anticancer effect. This combination effectively restored drug sensitivity and inhibited cellular proliferation more robustly than either agent alone. Transcriptomic analyses of cancer cells following fexofenadine treatment revealed significant modulation of gene expression profiles enriched in metastasis-related biological pathways, suggesting that fexofenadine might impact tumor progression and metastatic potential beyond merely overcoming resistance.

To bridge laboratory findings with potential clinical utility, the research leveraged patient-derived tumor xenograft (PDX) models—a gold standard in cancer research for recapitulating the molecular heterogeneity and biological complexity of human tumors. Remarkably, mice implanted with osimertinib-resistant NSCLC PDX tumors exhibited significant tumor regression upon combined fexofenadine and osimertinib treatment compared to control or single-agent groups. Importantly, this antitumor effect was achieved without inducing notable toxicity or adverse effects in the animal models, highlighting the safety of the repurposed drug combination.

The implications of this study are profound, as it demonstrates the feasibility of repurposing a common antihistamine to target a pivotal resistance pathway in cancer therapy. By circumventing the costly and time-consuming traditional drug development pipeline, this approach expedites the translation of existing medications to address unmet clinical needs in oncology. Moreover, it underscores the power of integrating computational biology and chemical-protein interactome analyses to uncover hidden therapeutic potentials within the pharmacopeia.

Beyond the immediate impact on NSCLC treatment paradigms, these findings illuminate a broader principle: that drug resistance in cancer can be tactically reversed by rational drug repositioning guided by molecular interactome insights. This methodology could be generalized across various cancer types exhibiting resistance through distinct molecular mechanisms, heralding a new era of precision oncology therapeutics optimized through data-driven repurposing strategies.

Future clinical trials are warranted to evaluate the efficacy and safety of fexofenadine as an adjuvant to osimertinib in NSCLC patients exhibiting MET amplification-driven resistance. If successful, this could transform standard care protocols and greatly enhance patient outcomes by integrating an affordable, accessible drug into complex cancer regimens. Furthermore, comprehensive biomarker analyses may identify subpopulations most likely to benefit from this combination, facilitating personalized medicine approaches that are both effective and economically sustainable.

In summary, the pioneering work by Prof. Kenneth To, Dr. William Cho, and their collaborators underscores an exciting intersection of computational drug discovery, molecular oncology, and clinical pharmacology. By unveiling fexofenadine’s unexpected role as a MET inhibitor capable of overcoming osimertinib resistance, this research paves the way for innovative therapeutic combinations poised to extend survival and improve quality of life for lung cancer patients worldwide.

—

Subject of Research: Overcoming osimertinib resistance in non-small cell lung cancer through drug repurposing of fexofenadine as a MET inhibitor.

Article Title: Fexofenadine Overcomes Osimertinib Resistance by Inhibiting c‐Met in Non‐Small Cell Lung Cancer

News Publication Date: 14-Apr-2025

Web References: http://dx.doi.org/10.1002/mog2.70019

Image Credits: Kenneth To

Insilico Medicine’s dual inhibitor stands out due to its ability to maintain effectiveness against mutations that typically arise during treatment. This breakthrough is crucial, as therapy resistance remains one of the primary hurdles in oncology, particularly when targeting specific receptor pathways. Existing inhibitors often fall short when it comes to treating patients who develop resistance mutations, which significantly limits their clinical effectiveness. Therefore, the development of a compound that can effectively target both FGFR2 and FGFR3 while circumventing these mutations heralds a new era in cancer treatment.

The research team employed Insilico’s self-developed Chemistry42 platform, which integrates cutting-edge artificial intelligence and machine learning technologies. This platform played a critical role in designing and optimizing the structures needed for effective FGFR inhibition. Specifically, Chemistry42 facilitated the generation of a pyrrolopyrazine carboxamide core structure, setting the stage for subsequent molecular optimization and refinement. Harnessing the power of AI to advance drug discovery processes has become increasingly common, and Insilico’s work exemplifies how these technologies can lead to tangible clinical innovations.

One of the standout features of the investigational compound, designated as compound 10, is its robust selectivity. This compound exhibits a marked preference for FGFR2 and FGFR3 while sparing FGFR1 and FGFR4. Such selectivity is vital in minimizing off-target effects and ensuring that the therapeutic window is optimized for patient safety and treatment efficacy. Unlike many existing FGFR inhibitors, which can indiscriminately affect multiple receptor types, compound 10’s tailored action holds promise for delivering enhanced treatment outcomes with fewer side effects.

Furthermore, preclinical studies indicated that compound 10 not only demonstrated favorable pharmacodynamics but also induced tumor stasis or regression in gastric cancer mouse models. These findings underscore the compound’s potential as a viable cancer therapy, providing hope to patients battling aggressive malignancies where treatment options are limited. The favorable safety profile observed in these studies points towards its promise as a first-in-class treatment option among FGFR inhibitors.

The dual inhibitor’s success is a testament to the seamless integration of AI into drug development processes. Insilico Medicine’s innovative methodology not only accelerates identification and optimization of lead compounds but also embodies a more holistic approach to drug discovery, where data analysis, predictive modeling, and iterative design converge. As AI technology continues to mature, its role in tailoring personalized treatment regimens based on patient-specific biology becomes increasingly crucial.

This research aligns with Insilico’s long-standing commitment to utilizing generative AI for drug development, a concept that dates back to 2016, when the company first introduced this transformative approach in a peer-reviewed journal. Since then, the integration of AI-driven solutions has become integral to the Pharma.AI platform, which encompasses a wide array of applications, from target identification to molecular design. Insilico Medicine has navigated through numerous technical breakthroughs, leading to a portfolio that includes several preclinical candidates, all designed using AI principles.

Another notable milestone in Insilico Medicine’s portfolio is the lead compound ISM001-055, which has recently reported positive results from Phase IIa clinical trials. This compound’s journey from AI-driven discovery to clinical testing exemplifies how generative AI technology can reshape the landscape of drug development. These advancements open up a plethora of possibilities for developing novel therapeutic agents tailored to address unmet medical needs across various diseases, including fibrotic disorders and neurological diseases.

Looking ahead, Insilico Medicine is committed to furthering its exploration of compound 10, with additional investigations planned to fully understand its safety profile and potential in combination therapies. The quest for perfecting cancer treatments continues, and the integration of artificial intelligence represents a transformative approach to addressing the complexities of drug resistance and disease progression.

The published findings in the Journal of Medicinal Chemistry not only highlight the scientific curiosity driving Insilico’s research but also represent a significant leap forward in translational medicine. With the application of generative AI and advanced computational methods, the path from concept to clinic has never been more expedient. This innovation can potentially lead to more effective treatments for patients who are often left without adequate options.

As the landscape of cancer therapy continues to evolve, the tools and methodologies employed in Insilico’s research offer a glimpse into the future of medicine—one that is defined by smart, data-driven decisions that ultimately lead to better patient outcomes. The consistent integration of AI into pharmaceutical research promises a paradigm shift in how new drugs are discovered and developed, paving the way for next-generation therapies that could revolutionize oncological care.

In an era where time is of the essence in cancer treatment, the use of AI-powered platforms like Chemistry42 provides an efficient solution to an urgent problem: the delay in bringing effective therapies to market. As this research advances toward clinical application, the hope for patients with resistant forms of cancer brightens significantly, offering a message of optimism in a field that often grapples with challenges and setbacks.

As scientists and researchers continue their important work at the intersection of biotechnology and artificial intelligence, the potential for groundbreaking discoveries seems limitless. The collective efforts of innovators in this space will undoubtedly yield further advancements, not only in cancer therapy but also in myriad other diseases, heralding a new age of medicine driven by intelligence, creativity, and compassion for human health.

Subject of Research: Development of a novel FGFR2/3 dual inhibitor
Article Title: Discovery of Pyrrolopyrazine Carboxamide Derivatives as Potent and Selective FGFR2/3 Inhibitors that Overcome Mutant Resistance
News Publication Date: 31-Jan-2025
Web References: Insilico Medicine, Journal of Medicinal Chemistry
References: Yazhou Wang, Yihong Zhang, Jinxin Liu, Jichen Zhao, Chao Wang, Fanye Meng, Xin Cai, Man Zhang, Alex Aliper, Tao Liang, Feng Yan, Feng Ren, Jiong Lan, Qiang Lu, Fusheng Zhou, Alex Zhavoronkov, and Xiao Ding. Discovery of Pyrrolopyrazine Carboxamide Derivatives as Potent and Selective FGFR2/3 Inhibitors that Overcome Mutant Resistance. Journal of Medicinal Chemistry Article ASAP. DOI: 10.1021/acs.jmedchem.4c03205
Image Credits: Insilico Medicine

Keywords: Generative AI, Molecular structure, Drug resistance, Drug research, Tumor development